Xencor, Inc.
NASDAQ:XNCRBiotechnology
-$0.13 today
- Market cap
- $2.55B
- Beta
- 0.93
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$2.29
Volume 1.09M
Average 0.80M
Returns on capital
Xencor, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-14.5%
avg -9.7%
ROIC
-21.5%
avg -10.0%
ROA
-10.5%
avg -7.2%
Analysis
ROA is currently the strongest return metric at -10.5% versus its period average of -7.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Bassil I. Dahiyat | Co-Founder, Chief Executive Officer, President & Director | USD 1.24M | 56 | 546.32K | 0.74% |
John R. Desjarlais | Executive Vice President of Research & Chief Scientific Officer | USD 858.49K | 62 | 263.83K | 0.36% |
Bart Jan Cornelissen | Senior Vice President & Chief Financial Officer | USD 816.11K | 48 | 65.80K | 0.09% |
Celia E. Eckert | Senior Vice President, General Counsel & Corporate Secretary | USD 744.19K | 54 | — | — |
Jeffrey Chou | Senior Vice President of Clinical Development- Oncology | — | — | — | — |
Mark Osterman | Senior Vice President of Clinical Development (Autoimmune) | — | — | — | — |
Eric Kowack | Senior Vice President of Program Leadership & Alliance Management | — | — | — | — |
Kirk Rosemark | Senior Vice President of Regulatory Affairs & Quality Assurance | — | 61 | — | — |
Jennifer Sandoz | Senior VIce President of Human Resources | — | — | — | — |
Dane Vincent Leone | Executive Vice President & Chief Strategy Officer | — | — | — | — |
Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
21
$7.49M
Net Transaction Value
−$7.49M
Net selling
Most Active
Desjarlais John R
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 11, 26Nov 11, 2026 | Cornelissen Bart Jan Direct | Sell | $402.2K$402,182.00 |
| Nov 10, 26Nov 10, 2026 | RANIERI RICHARD J Direct | Sell | $2.7M$2,747,136.00 |
| Nov 10, 26Nov 10, 2026 | RANIERI RICHARD J Direct | Sell | $442.3K$442,299.48 |
| Jun 18, 26Jun 18, 2026 | Feigal Ellen Direct | Sell | $89.4K$89,369.58 |
| Jun 15, 26Jun 15, 2026 | Montgomery Alan Bruce Direct | Sell | $62.3K$62,337.84 |
| Jun 15, 26Jun 15, 2026 | GORMAN KEVIN CHARLES Direct | Sell | $92.7K$92,657.37 |
| Jun 15, 26Jun 15, 2026 | GUSTAFSON KURT A Direct | Sell | $67.4K$67,384.94 |
| Jun 15, 26Jun 15, 2026 | RANIERI RICHARD J Direct | Sell | $67.4K$67,384.94 |
| Apr 10, 26Apr 10, 2026 | Cornelissen Bart Jan Direct | Sell | $43K$42,990.46 |
| Mar 6, 26Mar 6, 2026 | Desjarlais John R Direct | Sell | $27.6K$27,571.29 |
1–10 of 21
Summary
Insiders reported 0 buys worth $0.00 and 21 sells worth $7.49M over the last 12 months. That adds up to net selling of $7.49M. Desjarlais John R was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -8.6% | +28.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.6% over three years. Forward estimates point to Revenue at +28.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Xencor, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about XNCR's management, answered from reported figures.
Who manages XNCR?
Xencor, Inc. (XNCR) lists 11 active executives. The top listed executive is Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President & Director.
Are XNCR insiders buying or selling?
Recent insider activity shows net buying of $31.46M.
Continue the stock analysis
Jump to another research area for this company.